TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06597461

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial release
Description: Graston massage technique was used in the application. In the application, the participant was placed in a prone position and the feet were left slightly outside the massage table. The application was performed on the entire plantar surface between the calcaneal tuberosity and metatarsophalangeal joints in the form of multidirectional strokes at 30-60 degrees with the GT 4 graston tool. The total application took an average of 5 minutes for each foot. An average of 60-70 strokes were performed per minute and 10 seconds of rest was given every minute. The application was performed as a single session by an expert physiotherapist.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo myofascial release
Description: Graston massage technique was used in the application. In the application, the participant was placed in a prone position and the feet were left slightly outside the massage table. The application was performed on the entire plantar surface between the calcaneal tuberosity and metatarsophalangeal joints in the form of multidirectional strokes at 30-60 degrees with the GT 4 graston tool. The total application took an average of 5 minutes for each foot. An average of 60-70 strokes were performed per minute and 10 seconds of rest was given every minute. The application was performed as a single session by an expert physiotherapist. Since it was a placebo application, no pressure was applied to the tissues by the physiotherapist during the strokes.
Study: NCT06596733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vit-A-Vision
Description: Participants will apply Vit-A-Vision ointment on a daily basis, up to 3 times daily per eye, for at least 30 days.
Study: NCT06591208

Intervention type: DEVICE
Group type: OTHER
Intervention: pulsed dye laser
Description: PDL (Cynosure - Chelmsford, MA-USA) wavelength 585 nm at a fluence 2.5-5 J/cm2, pulse duration of 0.5 ms and spot size 7 -10 mm

Intervention type: DEVICE
Group type: OTHER
Intervention: Carboxytherapy
Description: carboxytherapy (Carbo - Programmable automatic carbon dioxide therapy apparatus, MA-USA) that was automatically calibrated to adjust the flow rate, through regulation of infusion pressure and the dosage of CO2 in ml. the infusion velocity consequently was adjusted to a flow rate of 1 cc/. The injection performed slowly, subcutaneously, by tilting the needle at 15 degree using a sterile disposable insulin needle, with the depth adjusted at 2 mm. the gas volume per injection spot is 2ml with 1.5 cm spacing between each injection point. End point was skin distension with the gas giving the characteristic popcorn appearance.
Study: NCT06586814

Intervention type: OTHER
Group type: OTHER
Intervention: Suture
Description: Wound Closure

Intervention type: OTHER
Group type: OTHER
Intervention: Staple
Description: Wound Closure
Study: NCT06600503

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RehabLung mobile application
Description: Participants in the intervention group will receive in-person pulmonary rehabilitation during their surgical admission and access to a mobile pulmonary rehabilitation application for self-training. This program begins one month before surgery and continues for seven weeks after surgery. The application is designed to encourage participants to engage in pulmonary rehabilitation exercises from preoperative preparation through postoperative care. It offers guided chest breathing exercises, using visual and movement instructions created and remotely prescribed by a physical therapist. Participants will receive daily breathing exercise prescriptions throughout the study period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lung cancer postoperative standard care
Description: Participants in the usual care group will receive in-person pulmonary rehabilitation during surgical admission, pre-operative healthcare, and guidance on breathing exercises to practice before surgery. They will also receive post-operative breathing exercise prescriptions to follow at home.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthcare interactive Web Platform
Description: The healthcare interactive Web Platform provides patients with surgical information through animations. This includes an introduction to lung surgery, preparation procedures, answers to common patient questions, post-surgery wound care, and a brief guide to pulmonary rehabilitation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthcare interactive Web Platform
Description: The healthcare interactive Web Platform provides patients with surgical information through animations. This includes an introduction to lung surgery, preparation procedures, answers to common patient questions, post-surgery wound care, and a brief guide to pulmonary rehabilitation.
Study: NCT06590545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy
Description: A dosage of 1x10\^8 KYV-101 CAR+ T cells will be administered intravenously as a single infusion.
Study: NCT06594211

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACT-001 CAR-NK cell
Description: Subjects were distributed into three dosage groups, each receiving a single dose of CAR-NK cells at levels of 1×10\^8, 3×10\^8, and 9×10\^8 cells, respectively.
Study: NCT06601738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isomeric Hand Grip Exercises
Description: Patients will be instructed to squeeze and sustain the dynamometer for 2 min at 30% M.V.C. The dynamometer pointer which read the scale provided visual feedback to the subjects for the maintenance of the 30% M.V.C. This procedure will be repeated twice for each training session with a 5-minute rest in between.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Hand Grip Exercises
Description: Dynamic handgrip exercise was performed with both-sided, metronome-guided rhythmic hand contractions for 2min. The handgrip ring, closest to 20% of MVC, was chosen for DHE which was performed at a frequency of 30/min, acoustically indicated by a metronome beat.
Study: NCT06598215

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Duckett urethroplasty
Description: hybrid duckett urethroplasty vs modified duckett urethroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Duckett urethroplasty
Description: hybrid duckett urethroplasty vs modified duckett urethroplasty
Study: NCT06587048

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periapical surgery
Description: In piezo group, the periapical surgery will be performed using piezoelectric device.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: periapical surgery
Description: In conventional bur group, the periapical surgery will be performed using rotary burs.
Study: NCT06603129

Intervention type: DIAGNOSTIC_TEST
Intervention: prognostic nutritional index
Description: Prognostic nutritional index is an inflammation-based scoring that measures the nutritional and immunological status of patients and has been used to determine prognosis and predict postoperative complications.

Intervention type: DIAGNOSTIC_TEST
Intervention: prognostic nutritional index
Description: Prognostic nutritional index is an inflammation-based scoring that measures the nutritional and immunological status of patients and has been used to determine prognosis and predict postoperative complications.
Study: NCT06602609

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote Patient Monitoring Strategy
Description: Continuous remote monitoring with the SmartCardia device includes continuous heart rate and cardiac conduction rhythm tracking through a 7-lead ECG enhanced by machine learning. This system can detect cardiac rhythm disturbances, measure breathing and heart rate, and provide live-alert notifications. Daily 12-lead ECG will be collected from each patient for 7 days after discharge; patients are instructed to perform a daily 12-lead ECG on the SHL device, along with recording blood pressure and oxygen saturation levels. Each ECG is interpreted by the trial team, and a cardiologist\&#39;s interpretation is confirmed, and patients will undergo remote consultations with a cardiologist or research nurse each day if needed. During the initial 30 days of patient recruitment, if the individual exhibits potential cardiac symptoms, they can activate a remote consultation by performing an extra 12-lead ECG and recording blood pressure and oxygen saturation levels.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Medical Therapy
Description: No intervention is required. Patients in this arm will fill out a self-reported anxiety report (SHAI form) and provide recent admission information
Study: NCT06594640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome
Description: assigned dose according to the 3+3 dose-escalation design in part 1, RP2D in part 2, D2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab (R)
Description: 375mg/m2, D2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX)
Description: 750mg/m2, D2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristin
Description: 1.2mg/m2, maximum 2mg， D2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 60mg/m2, D2-6
Study: NCT06588231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual rehabilitation exercise training
Description: Under the guidance of a specialist, medium-and high-intensity interval training was conducted for 16 weeks, 3 times a week, 30-40 minutes each time, including the beginning of 5 minutes of warm-up and the last 5 minutes of cooling-off period, during which the exercise included 4 intervals, with the 85-95% pre intensity of HR reserve for 15-18 minutes, and then with the 50-70% pre intensity of HR reserve for 12-14 minutes, exercise for 3 minutes, and so on for 4 times. Warm-up and cooling-off periods can be done through stretching exercises, flexibility exercises (that is, neck, shoulders, upper back, buttocks and ankles) and low and medium intensity (50-70% heart rate reserve)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: optimal medical therapy ：aspirin, clopidogrel, statins.
Description: those in the control group were treated with routine antiplatelet drugs and lipid-lowering drugs after operation. Professional salesmen, according to the specific physical conditions of the patients, formulate corresponding recipes to ensure that the patients have a light diet, low salt, low fat and high nutritional value, and prohibit tobacco and alcohol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: optimal medical therapy ：aspirin, clopidogrel, statins.
Description: those in the control group were treated with routine antiplatelet drugs and lipid-lowering drugs after operation. Professional salesmen, according to the specific physical conditions of the patients, formulate corresponding recipes to ensure that the patients have a light diet, low salt, low fat and high nutritional value, and prohibit tobacco and alcohol.
Study: NCT05043454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT) Exercise
Description: Participants will exercise 4 days/week for 10 weeks using the High Intensity Interval Training (HIIT) protocol. Sessions can be conducted at home or at a gym with access to a cycle ergometer. Participants will undergo 2 supervised training sessions to learn the HIIT protocol. To record heart rate, session duration, and time at each exercise intensity, participants will be provided with an H10 Polar TM heart rate chest strap monitor and a Polar Beat/Polar Flow account. Participants will download the Polar Beat/Flow smart phone application to record exercise sessions and allow the researcher to conduct remote data monitoring. Research staff will contact participants twice per week to provide feedback.
Study: NCT06331299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UGN-103
Description: UGN-103 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-103 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
Study: NCT06263010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopregnanolone
Description: Allopregnanolone is a neurosteroid ( 3α,5α-tetrahydroprogesterone, 3α-hydroxy-5α-pregnan-20-one) and by-product of the metabolism of the hormone progesterone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopregnanolone
Description: Allopregnanolone is a neurosteroid ( 3α,5α-tetrahydroprogesterone, 3α-hydroxy-5α-pregnan-20-one) and by-product of the metabolism of the hormone progesterone.
Study: NCT06595407

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood analysis for loss-of-Y chromosome
Description: Analysis for the percentage of circulating leukocytes with loss-of-y chromosome

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood analysis for loss-of-Y chromosome
Description: Analysis for the percentage of circulating leukocytes with loss-of-y chromosome
Study: NCT05403437

Intervention type: OTHER
Intervention: Evaluation of pain
Description: Painful areas will be marked on the body chart. The presence and severity of pelvic girdle pain will be determined by the Visual Analog Scale (VAS).

Intervention type: OTHER
Intervention: Evaluation of pain
Description: Painful areas will be marked on the body chart. The presence and severity of pelvic girdle pain will be determined by the Visual Analog Scale (VAS).

Intervention type: OTHER
Intervention: Evaluation of pain
Description: Painful areas will be marked on the body chart. The presence and severity of pelvic girdle pain will be determined by the Visual Analog Scale (VAS).

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of pelvic girdle pain diagnostic tests
Description: Pelvic girdle pain diagnostic tests will be applied. The severity of the pain that occurs in positive tests will be evaluated with VAS.

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of pelvic girdle pain diagnostic tests
Description: Pelvic girdle pain diagnostic tests will be applied. The severity of the pain that occurs in positive tests will be evaluated with VAS.

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of pelvic girdle pain diagnostic tests
Description: Pelvic girdle pain diagnostic tests will be applied. The severity of the pain that occurs in positive tests will be evaluated with VAS.

Intervention type: OTHER
Intervention: Evaluation of activity limitation
Description: The Pelvic Girdle Questionnaire will be filled.

Intervention type: OTHER
Intervention: Evaluation of activity limitation
Description: The Pelvic Girdle Questionnaire will be filled.
Study: NCT05383937

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Speech Therapy INTENS-DYS
Description: During the six research month, children included in the intensive arm will benefit of two daily hours speech therapy during two weeks. Those one will be carried out between the second and the fourth month.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech Therapy INTENS-DYS
Description: During the six research month, children included in the intensive arm will benefit of two daily hours speech therapy during two weeks. Those one will be carried out between the second and the fourth month.
Study: NCT06595277

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuromuscular blockade
Description: Neuromuscular blockade will be measured in all patients using a quantitative measurement (TOFScan, IdMed, Marseille, France) during surgery and after surgery until either full neuromuscular recovery or time of scheduled extubation.
Study: NCT05737537

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: procalcitonin ,CRP and 1, 3- β -D- glucan in early diagnosis of invasive infections
Description: using of blood biomarkers (CRP ,procalcitonin and 1, 3- β -D- glucan) in early differentiation between fungal and bacterial infections in pediatric cancer patients in comparison to blood culture.
Study: NCT04967560

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: deep brain stimulation
Description: Both group will undergo the DBS surgery. Four weeks after surgery, all patients will visit the clinic with the DBS stimulation in the 'off' state for initial programming of electrical parameters for stimulation. At double-blind visit, the electrical stimulation will be actually 'turned on' immediately after the programming in true-stimulation group, while turn-off in the control group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: deep brain stimulation
Description: Both group will undergo the DBS surgery. Four weeks after surgery, all patients will visit the clinic with the DBS stimulation in the 'off' state for initial programming of electrical parameters for stimulation. At double-blind visit, the electrical stimulation will be actually 'turned on' immediately after the programming in true-stimulation group, while turn-off in the control group.
Study: NCT05191992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPR training with e-learning with a handmade mannequin.
Description: The group, who was given theory training with the e learning method, will be taught to make pillows and plastic bottles and cpr mannequins, and they will be asked to practice. Knowledge and skills assessment will be made before, immediately after and 1 month after the training.
Study: NCT05610332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab One course will last 21 days. Given once every 3 weeks at a dose of 200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab One course will last 21 days. Given once every 3 weeks at a dose of 200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin Taxol
Description: Albumin paclitaxel was administered intravenously (without pretreatment) for 30 min on the first day of each cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLOT scheme
Description: Docetaxel 50mg/m2, ivgtt, d1; Oxaliplatin 85 mg/m2, ivgtt, d1; Calcium folinate 200mg/m2, ivgtt, d1; 5-fluorouracil 2600mg/m2, 24h civ, d1,~4 cycles before and after operation, q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOT scheme
Description: Docetaxel 50mg/m2, ivgtt, d1; Oxaliplatin 85 mg/m2, ivgtt, d1; Calcium folinate 200mg/m2, ivgtt, d1; 5-fluorouracil 2600mg/m2, 24h civ, d1,~4 cycles before and after operation, q2w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLOT scheme
Description: Docetaxel 50mg/m2, ivgtt, d1; Oxaliplatin 85 mg/m2, ivgtt, d1; Calcium folinate 200mg/m2, ivgtt, d1; 5-fluorouracil 2600mg/m2, 24h civ, d1,~4 cycles before and after operation, q2w
Study: NCT03810131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 'A Bite of ACT' (BOA)
Description: An online Acceptance and Commitment Therapy transdiagnostic psychoeducational intervention called 'A Bite of ACT' (BOA)
Study: NCT06623240

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic Hope Biosciences adipose-derived mesenchymal stem cells
Description: Product: Allogeneic HB-adMSCs (Hope Biosciences adipose derived mesenchymal stem cells)~Dose determined by body weight:~* 50 million cells in 50mL saline: ≥ 10 kg to \< 22 kg~* 100 million cells in 100mL saline: ≥ 22 kg to \< 45 kg~* 200 million cells in 250mL saline: ≥ 45 kg Route: Intravenous Regimen: Weeks 0, 4, and 8 (Cohort 1: Group A and Cohort 2: Group AB) or Weeks 20, 24, and 28 (Cohort 2: Group BA)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic Hope Biosciences adipose-derived mesenchymal stem cells
Description: Product: Allogeneic HB-adMSCs (Hope Biosciences adipose derived mesenchymal stem cells)~Dose determined by body weight:~* 50 million cells in 50mL saline: ≥ 10 kg to \< 22 kg~* 100 million cells in 100mL saline: ≥ 22 kg to \< 45 kg~* 200 million cells in 250mL saline: ≥ 45 kg Route: Intravenous Regimen: Weeks 0, 4, and 8 (Cohort 1: Group A and Cohort 2: Group AB) or Weeks 20, 24, and 28 (Cohort 2: Group BA)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic Hope Biosciences adipose-derived mesenchymal stem cells
Description: Product: Allogeneic HB-adMSCs (Hope Biosciences adipose derived mesenchymal stem cells)~Dose determined by body weight:~* 50 million cells in 50mL saline: ≥ 10 kg to \< 22 kg~* 100 million cells in 100mL saline: ≥ 22 kg to \< 45 kg~* 200 million cells in 250mL saline: ≥ 45 kg Route: Intravenous Regimen: Weeks 0, 4, and 8 (Cohort 1: Group A and Cohort 2: Group AB) or Weeks 20, 24, and 28 (Cohort 2: Group BA)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline Solution 0.9%
Description: Product: Normal Saline Solution 0.9% Route: Intravenous Regimen: Weeks 0, 4, and 8 (Cohort 2: Group BA) or Weeks 20, 24, and 28 (Cohort 2: Group AB)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline Solution 0.9%
Description: Product: Normal Saline Solution 0.9% Route: Intravenous Regimen: Weeks 0, 4, and 8 (Cohort 2: Group BA) or Weeks 20, 24, and 28 (Cohort 2: Group AB)
Study: NCT06586047

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET imaging
Description: Imaging with FDG PET/CT and Pyl PET/CT
Study: NCT06592391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational innovation dynamic school day
Description: Schools will form a community of practice, and will be supported with regular workshop to develop a dynamic school day that matches the local context.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-learning on a dynamic school day
Description: Schools will form a community of practice, and will develop a dynamic school day that matches their local context using e-learning materials

Intervention type: OTHER
Group type: OTHER
Intervention: expert schools
Description: Schools that have developed a local dynamic school day without additional support
Study: NCT04774094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavicefta, Ceftazidime-Avibactam
Description: Participants will receive CAZ-AVI (2000 mg of ceftazidime and 500 mg of avibactam) administered by IV infusion in a volume of 100 mL at a constant rate over 2 hours.
Study: NCT05484635

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic laparoscopy and inguinal mesh removal
Description: Surgical examination and treatment of groin pain following inguinal hernia surgery by surgical exploration with a laparoscope or removal of mesh laparoscopically

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic laparoscopy
Description: Surgical examination through laparoscopy without removal of mesh